Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Bluebird Bio (NQ: BLUE )

0.3850 +0.0050 (+1.32%)
Streaming Delayed Price Updated: 9:43 AM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 317,497
Open 0.3800
Bid (Size) 0.3807 (6)
Ask (Size) 0.3850 (36)
Prev. Close 0.3800
Today's Range 0.3701 - 0.3869
52wk Range 0.2900 - 5.530
Shares Outstanding 82,900,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
FDA Probes Potential Life-Threatening Blood Cancer Risks Linked To Bluebird Bio's Skysona Gene Therapy
The FDA is investigating reports of life-threatening blood cancers linked to Skysona, a gene therapy for CALD. Providers are urged to consider safer alternatives and monitor patients for malignancies. 
Via Benzinga
Exposures Product Safety
JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options
Bluebird Bio's Q3 earnings report showed a narrower-than-expected EPS loss but missed sales targets, leading to a JP Morgan downgrade and cash concerns. 
Via Benzinga

Performance

YTD
-73.81%
-73.81%
1 Month
-21.72%
-21.72%
3 Month
-35.01%
-35.01%
6 Month
-57.01%
-57.01%
1 Year
-90.03%
-90.03%

More News

Read More
bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance
From bluebird bio, Inc.
Via Business Wire
Exploring bluebird bio's Earnings Expectations
Via Benzinga
bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results Call
From bluebird bio, Inc.
Via Business Wire
The Analyst Verdict: bluebird bio In The Eyes Of 5 Experts
Via Benzinga
What 4 Analyst Ratings Have To Say About bluebird bio
Via Benzinga
Earnings Scheduled For November 14, 2024
Via Benzinga
bluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition
From bluebird bio, Inc.
Via Business Wire
Worries Mount Over Cancer Risks in Bluebird Bio's Gene Therapy
Via Benzinga
bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From bluebird bio, Inc.
Via Business Wire
bluebird bio Announces Completion of its Q2 2024 Form 10-Q Filing
From bluebird bio, Inc.
Via Business Wire
Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.
Via Investor's Business Daily
Gene Therapy-Focused Bluebird Bio Restructures, Cuts Is Workforce By 25%, Seeks To Breakeven Next Year
Via Benzinga
bluebird bio Initiates Restructuring Intended to Optimize Cost Structure and Enable Quarterly Cash Flow Break-Even in the Second Half of 2025
From bluebird bio, Inc.
Via Business Wire
bluebird bio Announces Completion of its Restatement and filing of its 2023 Form 10-K and Q1 2024 Form 10-Q
From bluebird bio, Inc.
Via Business Wire
bluebird bio Announces September Investor Events
From bluebird bio, Inc.
Via Business Wire
bluebird bio Announces Receipt of Expected Notices from Nasdaq
From bluebird bio, Inc.
Via Business Wire
This Snowflake Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
Via Benzinga
bluebird bio Reports Second Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance
From bluebird bio, Inc.
Via Business Wire
bluebird bio Announces Second Quarter 2024 Results Call Date
From bluebird bio, Inc.
Via Business Wire
CS Diagnostics (OTC: FZRO) Acquisitions Announced, Landmark Agreement Signed, Moving Forward Through 2024
Via AB Newswire
Topics Intellectual Property
Exposures Intellectual Property
bluebird bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From bluebird bio, Inc.
Via Business Wire
BLUE ALERT: Bragar Eagel & Squire, P.C. is Investigating Bluebird bio Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
bluebird bio Reports Inducement Grant to CFO James Sterling Under Nasdaq Listing Rule 5635(c)(4)
From bluebird bio, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.